Abstract
Reactivation of hepatitis B infection is an increasing problem for patients with lymphoma, even in resolved infections, who were treated with rituximab-based regimens. Our cases point out the need of prolonged prophylaxis in HBsAg-negative patients due to the high risk of developing fatal reactivation.
Copyright 2008 Wiley-Liss, Inc.
MeSH terms
-
Aged
-
Antibodies, Monoclonal / adverse effects*
-
Antibodies, Monoclonal, Murine-Derived
-
Female
-
Guanine / analogs & derivatives
-
Guanine / therapeutic use
-
Hepatitis B / chemically induced*
-
Hepatitis B / drug therapy
-
Humans
-
Lymphoma, B-Cell / complications
-
Lymphoma, B-Cell / drug therapy
-
Middle Aged
-
Rituximab
-
Treatment Outcome
-
Virus Activation / drug effects*
Substances
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Murine-Derived
-
Rituximab
-
entecavir
-
Guanine